A Randomized, Controlled Clinical Trial Demonstrates Improved Cognitive Function in Senior Dogs Supplemented with a Senolytic and NAD+ Precursor Combination

Katherine E. Simon,Katharine Russell,Alejandra Mondino,Chin-Chieh Yang,Beth C Case,Zachary Anderson,Christine Whitley,Emily Griffith,Margaret E. Gruen,Natasha J. Olby

DOI: https://doi.org/10.1101/2024.02.26.581616

2024-02-28

Abstract:Age-related decline in mobility and cognition are associated with cellular senescence and NAD+ depletion in dogs and people. A combination of a novel NAD+ precursor and senolytic, LY-D6/2 was examined in this randomized controlled trial. Seventy dogs were enrolled and allocated into placebo, low or full dose groups. Primary outcomes were change in cognitive impairment measured with the owner-reported Canine Cognitive Dysfunction Rating (CCDR) scale and change in activity measured with physical activity monitors. Fifty-nine dogs completed evaluations at the three-month primary endpoint, and 51 reached the six-month secondary endpoint. There was a significant difference in CCDR score across treatment groups from baseline to the primary endpoint (p=0.02) with the largest decrease in the full dose group. There were no significant differences between groups in changes in measured activity. However, the proportion of dogs that improved in frailty and owner-reported activity levels and happiness was higher in the full dose group than other groups. Adverse events occurred equally across groups. All groups showed improvement in cognition, frailty, and activity suggesting placebo effect and benefits of trial participation. We conclude that LY-D6/2 significantly improves owner-assessed cognitive function and may have broader effects on frailty, activity and happiness as reported by owners.

Animal Behavior and Cognition

What problem does this paper attempt to address?

This paper discusses a randomized controlled clinical trial that investigated the effects of a supplement combining a senolytic agent and NAD+ precursor on the cognitive function of elderly dogs. The main question of the study was whether this combination supplement could improve cognitive impairment and activity levels in aging dogs. In the trial, 70 dogs aged 10 and above were randomly assigned to placebo, low-dose, or full-dose groups, and the primary outcomes were canine cognitive dysfunction rating (CCDR) reported by owners and activity changes measured by activity monitors.

The study found that at the 3-month primary endpoint, the full-dose group showed the most significant improvement in CCDR scores, indicating a reduction in cognitive decline. However, there were no significant differences in activity level changes among the groups. Nevertheless, a higher proportion of dogs in the full-dose group showed improvements in frailty, activity level, and well-being. During the trial, improvements in cognition, frailty, and activity in all groups could be partially attributed to placebo effects and the benefits of participating in the trial. Additionally, the supplement overall was well-tolerated, with adverse events evenly distributed among the groups.

In conclusion, this study aimed to address how cognitive decline in elderly dogs can be mitigated by specific nutritional supplements and potentially improve their quality of life. The results showed that this combination supplement had a significant improvement in owner-assessed cognitive function but had no significant effect on activity levels.